Show simple item record

dc.contributor.authorMedeiros, Iara Marques de [UNIFESP]
dc.contributor.authorReed, S.
dc.contributor.authorCastelo Filho, Adauto [UNIFESP]
dc.contributor.authorSalomão, Reinaldo [UNIFESP]
dc.date.accessioned2016-01-24T12:30:57Z
dc.date.available2016-01-24T12:30:57Z
dc.date.issued2000-01-01
dc.identifierhttp://dx.doi.org/10.1046/j.1469-0691.2000.00011.x
dc.identifier.citationClinical Microbiology and Infection. Oxford: Blackwell Science Ltd, v. 6, n. 1, p. 34-37, 2000.
dc.identifier.issn1198-743X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/26202
dc.description.abstractObjective To study the influence of soluble tumour necrosis factor (TNF) receptors (sTNFR) on bioactivity; and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis (Kala-azar) and to examine the association between circulating levels of sTNFR type I and type IT with clinical manifestations of the disease.Methods Ten patients with Kala-azar were enrolled. Plasma samples for TNF-alpha and sTNFR were obtained on days 0, 7 and 21-28 of antimonial therapy. Bioactivity of TNF-alpha was measured by cytotoxicity to L-929 cells and immunoreactivity by enzyme-linked immunosorbent assay (ELISA). sTNFR-I and sTNFR-II were measured by ELISA.Results Measured by ELISA, TNF-alpha was detected at baseline in all patients (range from 22.3 to 163 pg/mL) and showed a linear decline over time on therapy (r = -0.49, P = 0.007). in contrast, when measured by cytotoxicity assay, TNF-alpha was detected in only one patient at baseline (193 pg/mL) and in four patients at the end of therapy (38.7, 95, 133 and 232 pg/mL) and there was no linear association between TNF-alpha. and duration of therapy (r = -0.18, P = 0.45). sTNFR-I and sTNFR-II were detected in all patients before therapy. There was a strong positive correlation between plasma concentrations of sTNFR-I and sTNFR-II (r = 0.8, P = 0.006). Levels of sTNFR-I and sTNFR-II declined exponentially with time on therapyConclusions We concluded that sTNFR-I and sTNFR-II are related to disease activity in patients with Kala-azar and that these circulating receptors may interfere with the biological activity of TNF-alpha in patients with Kala-azar.en
dc.format.extent34-37
dc.language.isoeng
dc.publisherBlackwell Science Ltd
dc.relation.ispartofClinical Microbiology and Infection
dc.rightsAcesso aberto
dc.subjectvisceral leishmaniasisen
dc.subjecttumour necrosis factoren
dc.subjectsoluble tumour necrosis factor receptoren
dc.subjectsTNFRen
dc.titleCirculating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasisen
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniv Fed Rio Grande Norte
dc.contributor.institutionInfect Dis Res Inst
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, UNIFESP, BR-04023900 São Paulo, SP, Brazil
dc.description.affiliationUniv Fed Rio Grande Norte, BR-59072970 Natal, RN, Brazil
dc.description.affiliationInfect Dis Res Inst, Seattle, WA USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, UNIFESP, BR-04023900 São Paulo, SP, Brazil
dc.identifier.doi10.1046/j.1469-0691.2000.00011.x
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000086861000007


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record